LSU Anxiety and Mood Disorders Clinic
New Orleans, Louisiana, 70115, United States
NCT Number: NCT00595699
This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
New Orleans, Louisiana, 70115, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
Other names: Lexapro
Placebo
Time frame: Screen, Baseline, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 10
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 10
Conrad, Erich J., M.D.
Other
Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy. A Double-blind, Placebo-controlled Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05497414
Depressive Disorder, Depressive Disorder, Major
Boston, Massachusetts, United States
View Trial DetailsNCT05257902
Depressive Disorder, Depressive Disorder, Major
Seoul, Irwon-dong, Gangnam-gu, South Korea
View Trial DetailsNCT01962753
Depressive Disorder, Depressive Disorder, Major
Besançon, France
View Trial DetailsNCT06748274
Autonomous Dysfunction, Behavior
Bern, Canton of Bern, Switzerland
View Trial Details